Company Overview
Snapshot
Founded in November 2013 by Joseph Flomenblit, S.T. Stent operates with 1–10 employees. The company has raised $1.76M across 4 funding rounds from 4 investors.
Business overview
S.T. Stent develops and commercializes a composite, removable sinus stent designed for placement in the ethmoid sinus following functional endoscopic sinus surgery. This technology aims to keep the sinus cavity open for up to 28 days, improving patient outcomes by reducing the likelihood of revision surgeries. The stent adapts to patient anatomy, is made from biocompatible materials, and can be easily removed in a minimally invasive office procedure without anesthesia. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics for healthcare providers globally.
Strategic signal
In June 2022, S.T. Stent's technology was highlighted for its potential to revolutionize sinus surgery outcomes. This recognition underscores the company's commitment to advancing medical devices that offer significant improvements in patient care and recovery, signaling strong clinical validation and market potential for its innovative stent solution.
Log in to access full profile ›Company Intelligence Q&A
- What is S.T. Stent's core product?
- S.T. Stent develops a composite, removable sinus stent designed to keep the ethmoid sinus cavity open for up to 28 days after functional endoscopic sinus surgery, aiming to improve patient outcomes and reduce revision surgeries.
- When did S.T. Stent receive FDA clearance for its sinus stent?
- S.T. Stent was awarded FDA clearance for its sinus stent in January 2018, as reported by multiple sources including Medgadget and PR Newswire.
- Which investors participated in S.T. Stent's November 2022 funding round?
- In November 2022, S.T. Stent received funding from ExitValley and The Trendlines Group.
- When did S.T. Stent complete a $450k raise?
- S.T. Stent completed a $450k raise in April 2015, with participation from The Trendlines Group.